About us

Affinicon was founded in 2013 and has 3 employees, exploits a novel platform technology for targeted delivery of known drugs to macrophages. The combinatory drugs have a high safety profile for the treatment of diseases where macrophages play a key role such as inflammation, infections, and certain forms of cancer. The development of receptor-targeted therapeutics will focus on the macrophage specific receptor CD163, the most abundant transport receptor on macrophages.

Affinicon acquired all intellectual property rights from Cytoguide as of October 2013, and continues the project of Cytogudies

Affinicon ApS Science Park Aarhus, Aabogade 15, 8200 Aarhus N